Posted by Michael Wonder on 30 Apr 2024
Gefapixant for the treatment of patients with refractory or unexplained chronic cough
30 April 2024 - NICE is unable to make a recommendation on the use of gefapixant (Lyfnua) for the treatment of adults with refractory or unexplained chronic cough because Merck/MSD did not provide an evidence submission.
NICE will review this decision if Merck/MSD decides to make a submission.
